KBC Group
ITOS

KBC Group’s iTeos Therapeutics ITOS Stock Holding History

KBC Group’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,773
Closed -$23K – 1930
2023
Q2 		$23K Hold
1,773
– – ﹤0.01% 1462
2023
Q1 		$24K Hold
1,773
– – ﹤0.01% 1480
2022
Q4 		$35K Hold
1,773
– – ﹤0.01% 1459
2022
Q3 		$34K Hold
1,773
– – ﹤0.01% 1463
2022
Q2 		$37K Buy
+1,773
New +$42.1K ﹤0.01% 1472

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

KBC Group's ITOS Position: Q3 2023 in Review

KBC Group sold out of iTeos Therapeutics (ITOS) in Q3 2023, closing a stake of 1,773 shares — an estimated $23K sold.

KBC Group first reported a position in ITOS in Q2 2022 and held it in 5 quarters. The position peaked at $37K in Q2 2022. 144 funds tracked by Wall St. Rank hold ITOS as of Q3 2023.

  • KBC Group reported no remaining iTeos Therapeutics position as of Q3 2023 after selling out during the quarter.
  • KBC Group sold 1,773 iTeos Therapeutics shares in Q3 2023, an estimated $23K.
  • KBC Group first reported a position in iTeos Therapeutics in Q2 2022 and held it in 5 quarters.
  • KBC Group's iTeos Therapeutics position peaked at $37K in Q2 2022.
  • 144 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2023.

Based on KBC Group's 13F filing for Q3 2023, filed 22 Nov 2023.